Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 1,849

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology

Open access
Authors/Task Force Members, Bassand, J.-P., Hamm, C. W., Ardissino, D., Boersma, E., Budaj, A., Fernandez-Aviles, F., Fox, K. A.A., Hasdai, D., Ohman, E. M., Wallentin, L., Wijns, W., ESC Committee for Practice Guidelines (CPG), Vahanian, A., Camm, J., De Caterina, R., Dean, V., Dickstein, K., Filippatos, G., Kristensen, S. D., Widimsky, P., McGregor, K., Sechtem, U., Tendera, M., Hellemans, I., Gomez, J. L. Z., Silber, S., Funck-Brentano, C., Document Reviewers, Kristensen, S. D., Andreotti, F., Benzer, W., Bertrand, M., Betriu, A., De Caterina, R., DeSutter, J., Falk, V., Ortiz, A. F., Gitt, A., Hasin, Y., Huber, K., Kornowski, R., Lopez-Sendon, J., Morais, J., Nordrehaug, J. E., Silber, S., Steg, P. G., Thygesen, K., Tubaro, M., Turpie, A. G.G., Verheugt, F., Windecker, S.·2007·European Heart Journal
DOI 10.1093/eurheartj/ehm161
Open this paper in CoChat — free account

Abstract

antagonists . . . . . . . . . . . . .1614 5.2.6 Anticoagulants during percutaneous coronary intervention procedures in non-STsegment elevation acute coronary syndromes . . . . . . . . . . . . . . . . . . .1615 5.3 Antiplatelet agents . . . . . . . . . . . . . . . .1616 5.3.1 Acetylsalicylic acid (aspirin) . . . . . . . . .1616 5.3.2Thienopyridines . . . . . . . . . . . . . . . .1617 5.3.3Glycoprotein IIb/IIIa receptor inhibitors . .1618 5.3.4Resistance to antiplatelet agents/drug interactions . . . . . . . . . . . . . . . . . .1621 5.3.5 Withdrawal of antiplatelet agents . . . . . .1622 5.4 Coronary revascularization . . . . . . . . . . .1623 5.4.1 Coronary angiography . . . . . . . . . . . . .1623 5.4.2Invasive vs. conservative strategy . . . . . .1623 5.4.3Percutaneous coronary intervention . . . . .1625 5.4.4Coronary artery bypass graft . . . . . . . . .1625 5.4.5 Respective indications for percutaneous coronary intervention or coronary artery bypass graft . . . . . . . . . . . . . . . . . .

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehm161

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 483

  1. Murray, 1997, Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study, Lancet, 349, 1498, 10.1016/S0140-6736(96)07492-2 · DOI · Paper page
  2. Van de Werf, 2003, Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology, Eur Heart J, 24, 28, 10.1016/S0195-668X(02)00618-8 · DOI · Paper page
  3. Bertrand, 2002, Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation, Eur Heart J, 23, 1809, 10.1053/euhj.2002.3385 · DOI · Paper page
  4. Alpert, 2000, Myocardial infarction redefined—a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction, Eur Heart J, 21, 1502, 10.1053/euhj.2000.2305 · DOI · Paper page
  5. 2001, GRACE Investigators. Rationale and design of the GRACE (Global Registry of Acute Coronary Events) project: a multinational registry of patients hospitalized with acute coronary syndromes, Am Heart J, 141, 190, 10.1067/mhj.2001.112404 · DOI · Paper page
  6. Birkhead, 2004, Improving care for patients with acute coronary syndromes: initial results from the National Audit of Myocardial Infarction Project (MINAP), Heart, 90, 1004, 10.1136/hrt.2004.034470 · DOI
  7. Eagle, 2004, A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry, JAMA, 291, 2727, 10.1001/jama.291.22.2727 · DOI · Paper page
  8. Fox, 2002, Management of acute coronary syndromes. Variations in practice and outcome; findings from the Global Registry of Acute Coronary Events (GRACE), Eur Heart J, 23, 1177, 10.1053/euhj.2001.3081 · DOI · Paper page
  9. Hasdai, 2003, Cardiac biomarkers and acute coronary syndromes—the Euro Heart Survey of Acute Coronary Syndromes Experience, Eur Heart J, 24, 1189, 10.1016/S0195-668X(03)00204-5 · DOI
  10. Hasdai, 2002, A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin; the Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS), Eur Heart J, 23, 1190, 10.1053/euhj.2002.3193 · DOI · Paper page
  11. Hoekstra, 2002, Improving the care of patients with non-ST-elevation acute coronary syndromes in the emergency department: the CRUSADE initiative, Acad Emerg Med, 9, 1146
  12. Lev, 2003, Frequency, characteristics, and outcome of patients hospitalized with acute coronary syndromes with undetermined electrocardiographic patterns, Am J Cardiol, 91, 224, 10.1016/S0002-9149(02)03111-9 · DOI
  13. Stenestrand, 2001, Early statin treatment following acute myocardial infarction and 1-year survival, JAMA, 285, 430, 10.1001/jama.285.4.430 · DOI · Paper page
  14. Stenestrand, 2002, Early revascularisation and 1-year survival in 14-day survivors of acute myocardial infarction: a prospective cohort study, Lancet, 359, 1805, 10.1016/S0140-6736(02)08710-X · DOI
  15. Goldberg, 1986, Recent changes in attack and survival rates of acute myocardial infarction (1975 through 1981). The Worcester Heart Attack Study, JAMA, 255, 2774, 10.1001/jama.1986.03370200076031 · DOI
  16. Bata, 2000, Trends in the incidence of acute myocardial infarction between 1984 and 1993—The Halifax County MONICA Project, Can J Cardiol, 16, 589
  17. Fox, 2000, The ENACT study: a pan-European survey of acute coronary syndromes. European Network for Acute Coronary Treatment, Eur Heart J, 21, 1440, 10.1053/euhj.2000.2185 · DOI
  18. Furman, 2001, Twenty-two year (1975 to 1997) trends in the incidence, in-hospital and long-term case fatality rates from initial Q-wave and non-Q-wave myocardial infarction: a multi-hospital, community-wide perspective, J Am Coll Cardiol, 37, 1571, 10.1016/S0735-1097(01)01203-7 · DOI
  19. van der Pal-de Bruin, 1998, The incidence of suspected myocardial infarction in Dutch general practice in the period 1978–1994, Eur Heart J, 19, 429, 10.1053/euhj.1997.0766 · DOI
  20. Savonitto, 1999, Prognostic value of the admission electrocardiogram in acute coronary syndromes, JAMA, 281, 707, 10.1001/jama.281.8.707 · DOI · Paper page
  21. Volmink, 1998, Coronary event and case fatality rates in an English population: results of the Oxford myocardial infarction incidence study. The Oxford Myocardial Infarction Incidence Study Group, Heart, 80, 40, 10.1136/hrt.80.1.40 · DOI
  22. Terkelsen, 2005, Mortality rates in patients with ST-elevation vs. non-ST-elevation acute myocardial infarction: observations from an unselected cohort, Eur Heart J, 26, 18, 10.1093/eurheartj/ehi002 · DOI · Paper page
  23. Bahit, 2002, Persistence of the prothrombotic state after acute coronary syndromes: implications for treatment, Am Heart J, 143, 205, 10.1067/mhj.2002.120767 · DOI
  24. Bogaty, 2001, Biological profiles in subjects with recurrent acute coronary events compared with subjects with long-standing stable angina, Circulation, 103, 3062, 10.1161/01.CIR.103.25.3062 · DOI
  25. Hamm, 2006, Acute coronary syndromes: pathophysiology, diagnosis and risk stratification, p333
  26. Davies, 2000, The pathophysiology of acute coronary syndromes, Heart, 83, 361, 10.1136/heart.83.3.361 · DOI · Paper page
  27. Libby, 2001, Current concepts of the pathogenesis of the acute coronary syndromes, Circulation, 104, 365, 10.1161/01.CIR.104.3.365 · DOI · Paper page
  28. Hansson, 2002, Innate and adaptive immunity in the pathogenesis of atherosclerosis, Circ Res, 91, 281, 10.1161/01.RES.0000029784.15893.10 · DOI · Paper page
  29. Falk, 1985, Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death. Autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion, Circulation, 71, 699, 10.1161/01.CIR.71.4.699 · DOI · Paper page
  30. Davies, 1986, Intramyocardial platelet aggregation in patients with unstable angina suffering sudden ischemic cardiac death, Circulation, 73, 418, 10.1161/01.CIR.73.3.418 · DOI · Paper page
  31. Mizuno, 1992, Angioscopic evaluation of coronary-artery thrombi in acute coronary syndromes, N Engl J Med, 326, 287, 10.1056/NEJM199201303260502 · DOI · Paper page
  32. Ardissino, 1997, Tissue-factor antigen and activity in human coronary atherosclerotic plaques, Lancet, 349, 769, 10.1016/S0140-6736(96)11189-2 · DOI
  33. Lindahl, 2000, Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease, N Engl J Med, 343, 1139, 10.1056/NEJM200010193431602 · DOI · Paper page
  34. Liuzzo, 1994, The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina, N Engl J Med, 331, 417, 10.1056/NEJM199408183310701 · DOI · Paper page
  35. Rioufol, 2002, Multiple atherosclerotic plaque rupture in acute coronary syndrome: a three-vessel intravascular ultrasound study, Circulation, 106, 804, 10.1161/01.CIR.0000025609.13806.31 · DOI · Paper page
  36. Fichtlscherer, 2004, Prognostic value of systemic endothelial dysfunction in patients with acute coronary syndromes: further evidence for the existence of the ‘vulnerable’ patient, Circulation, 110, 1926, 10.1161/01.CIR.0000143378.58099.8C · DOI · Paper page
  37. Schachinger, 2000, Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease, Circulation, 101, 1899, 10.1161/01.CIR.101.16.1899 · DOI · Paper page
  38. Bugiardini, 2005, Angina with ‘normal’ coronary arteries: a changing philosophy, JAMA, 293, 477, 10.1001/jama.293.4.477 · DOI · Paper page
  39. Kaski, 1995, Rapid angiographic progression of coronary artery disease in patients with angina pectoris. The role of complex stenosis morphology, Circulation, 92, 2058, 10.1161/01.CIR.92.8.2058 · DOI
  40. Tofler, 2006, Triggering of acute cardiovascular disease and potential preventive strategies, Circulation, 114, 1863, 10.1161/CIRCULATIONAHA.105.596189 · DOI · Paper page
  41. Skyschally, 2006, Coronary microembolization, Basic Res Cardiol, 101, 373, 10.1007/s00395-006-0616-1 · DOI
  42. Campeau, 1976, Letter: Grading of angina pectoris, Circulation, 54, 522, 10.1161/circ.54.3.947585 · DOI · Paper page
  43. van Domburg, 1998, Unstable angina: good long-term outcome after a complicated early course, J Am Coll Cardiol, 31, 1534, 10.1016/S0735-1097(98)00140-5 · DOI
  44. Culic, 2002, Symptom presentation of acute myocardial infarction: influence of sex, age, and risk factors, Am Heart J, 144, 1012, 10.1067/mhj.2002.125625 · DOI
  45. Brieger, 2004, Acute coronary syndromes without chest pain, an underdiagnosed and undertreated high-risk group: insights from the Global Registry of Acute Coronary Events, Chest, 126, 461, 10.1378/chest.126.2.461 · DOI · Paper page
  46. Braunwald, 1989, Unstable angina. A classification, Circulation, 80, 410, 10.1161/01.CIR.80.2.410 · DOI · Paper page
  47. van Miltenburg-van Zijl, 1995, Incidence and follow-up of Braunwald subgroups in unstable angina pectoris, J Am Coll Cardiol, 25, 1286, 10.1016/0735-1097(95)00009-S · DOI
  48. Hamm, 2000, A classification of unstable angina revisited, Circulation, 102, 118, 10.1161/01.CIR.102.1.118 · DOI · Paper page
  49. Diercks, 2006, Frequency and consequences of recording an electrocardiogram > 10 min after arrival in an emergency room in non-ST-segment elevation acute coronary syndromes (from the CRUSADE Initiative), Am J Cardiol, 97, 437, 10.1016/j.amjcard.2005.09.073 · DOI
  50. Cannon, 1997, The electrocardiogram predicts one-year outcome of patients with unstable angina and non-Q wave myocardial infarction: results of the TIMI III Registry ECG Ancillary Study. Thrombolysis in Myocardial Ischemia, J Am Coll Cardiol, 30, 133, 10.1016/S0735-1097(97)00160-5 · DOI · Paper page
  51. Holmvang, 2003, Quantitative analysis of the admission electrocardiogram identifies patients with unstable coronary artery disease who benefit the most from early invasive treatment, J Am Coll Cardiol, 41, 905, 10.1016/S0735-1097(02)02970-4 · DOI
  52. Hyde, 1999, Four-year survival of patients with acute coronary syndromes without ST-segment elevation and prognostic significance of 0.5-mm ST-segment depression, Am J Cardiol, 84, 379, 10.1016/S0002-9149(99)00319-7 · DOI
  53. Kaul, 2001, Prognostic value of ST segment depression in acute coronary syndromes: insights from PARAGON-A applied to GUSTO-IIb. PARAGON-A and GUSTO IIb Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute Global Organization Network, J Am Coll Cardiol, 38, 64, 10.1016/S0735-1097(01)01307-9 · DOI
  54. Nyman, 1993, Very early risk stratification by electrocardiogram at rest in men with suspected unstable coronary heart disease. The RISC Study Group, J Intern Med, 234, 293, 10.1111/j.1365-2796.1993.tb00746.x · DOI
  55. de Zwaan, 1989, Angiographic and clinical characteristics of patients with unstable angina showing an ECG pattern indicating critical narrowing of the proximal LAD coronary artery, Am Heart J, 117, 657, 10.1016/0002-8703(89)90742-4 · DOI
  56. McCarthy, 1990, Detecting acute cardiac ischemia in the emergency department: a review of the literature, J Gen Intern Med, 5, 365, 10.1007/BF02600409 · DOI
  57. Rouan, 1989, Clinical characteristics and outcome of acute myocardial infarction in patients with initially normal or nonspecific electrocardiograms (a report from the Multicenter Chest Pain Study), Am J Cardiol, 64, 1087, 10.1016/0002-9149(89)90857-6 · DOI
  58. Akkerhuis, 2001, Recurrent ischaemia during continuous multilead ST-segment monitoring identifies patients with acute coronary syndromes at high risk of adverse cardiac events; meta-analysis of three studies involving 995 patients, Eur Heart J, 22, 1997, 10.1053/euhj.2001.2750 · DOI
  59. Gottlieb, 1986, Silent ischemia as a marker for early unfavorable outcomes in patients with unstable angina, N Engl J Med, 314, 1214, 10.1056/NEJM198605083141903 · DOI · Paper page
  60. Jernberg, 2000, The combination of a continuous 12-lead ECG and troponin T; a valuable tool for risk stratification during the first 6 h in patients with chest pain and a non-diagnostic ECG, Eur Heart J, 21, 1464, 10.1053/euhj.2000.2178 · DOI
  61. Patel, 1996, Early continuous ST segment monitoring in unstable angina: prognostic value additional to the clinical characteristics and the admission electrocardiogram, Heart, 75, 222, 10.1136/hrt.75.3.222 · DOI
  62. Nyman, 1993, Risk stratification by early exercise testing after an episode of unstable coronary artery disease. The RISC Study Group, Int J Cardiol, 39, 131, 10.1016/0167-5273(93)90024-B · DOI
  63. Eggers, 2004, Diagnostic value of serial measurement of cardiac markers in patients with chest pain: limited value of adding myoglobin to troponin I for exclusion of myocardial infarction, Am Heart J, 148, 574, 10.1016/j.ahj.2004.04.030 · DOI
  64. Thygesen, Universal definition of myocardial infarction, Personal Communication
  65. Hamm, 1992, The prognostic value of serum troponin T in unstable angina, N Engl J Med, 327, 146, 10.1056/NEJM199207163270302 · DOI · Paper page
  66. James, 2003, N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy, Circulation, 108, 275, 10.1161/01.CIR.0000079170.10579.DC · DOI · Paper page
  67. Lindahl, 2001, Mechanisms behind the prognostic value of troponin T in unstable coronary artery disease: a FRISC II substudy, J Am Coll Cardiol, 38, 979, 10.1016/S0735-1097(01)01501-7 · DOI
  68. Cannon, 2001, Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban, N Engl J Med, 344, 1879, 10.1056/NEJM200106213442501 · DOI · Paper page
  69. Hamm, 1999, Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators, N Engl J Med, 340, 1623, 10.1056/NEJM199905273402103 · DOI · Paper page
  70. Heeschen, 1999, Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. PRISM Study Investigators. Platelet Receptor Inhibition in Ischemic Syndrome Management, Lancet, 354, 1757, 10.1016/S0140-6736(99)10285-X · DOI · Paper page
  71. Hamm, 1997, Emergency room triage of patients with acute chest pain by means of rapid testing for cardiac troponin T or troponin I, N Engl J Med, 337, 1648, 10.1056/NEJM199712043372302 · DOI · Paper page
  72. Apple, 2002, Predictive value of cardiac troponin I and T for subsequent death in end-stage renal disease, Circulation, 106, 2941, 10.1161/01.CIR.0000041254.30637.34 · DOI · Paper page
  73. Aviles, 2002, Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction, N Engl J Med, 346, 2047, 10.1056/NEJMoa013456 · DOI · Paper page
  74. Heeschen, 2000, Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. CAPTURE Investigators. Chimeric c7E3 AntiPlatelet Therapy in Unstable angina REfractory to standard treatment trial, J Am Coll Cardiol, 35, 1535, 10.1016/S0735-1097(00)00581-7 · DOI · Paper page
  75. Morrow, 1998, C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in myocardial infarction, J Am Coll Cardiol, 31, 1460, 10.1016/S0735-1097(98)00136-3 · DOI · Paper page
  76. de Winter, 2003, C-reactive protein and coronary events following percutaneous coronary angioplasty, Am J Med, 115, 85, 10.1016/S0002-9343(03)00238-9 · DOI
  77. de Lemos, 2001, The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes, N Engl J Med, 345, 1014, 10.1056/NEJMoa011053 · DOI · Paper page
  78. Jernberg, 2002, N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation, J Am Coll Cardiol, 40, 437, 10.1016/S0735-1097(02)01986-1 · DOI
  79. Heeschen, 2004, N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes, Circulation, 110, 3206, 10.1161/01.CIR.0000147611.92021.2B · DOI · Paper page
  80. Weber, 2006, Release pattern of N-terminal pro B-type natriuretic peptide (NT-proBNP) in acute coronary syndromes, Clin Res Cardiol, 95, 270, 10.1007/s00392-006-0375-x · DOI
  81. Mueller, 2006, Cost-effectiveness of B-type natriuretic peptide testing in patients with acute dyspnea, Arch Intern Med, 166, 1081, 10.1001/archinte.166.10.1081 · DOI
  82. Al Suwaidi, 2002, Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes, Circulation, 106, 974, 10.1161/01.CIR.0000027560.41358.B3 · DOI · Paper page
  83. Masoudi, 2004, Renal insufficiency and mortality from acute coronary syndromes, Am Heart J, 147, 623, 10.1016/j.ahj.2003.12.010 · DOI
  84. Weber, 1991, Interferences in current methods for measurements of creatinine, Clin Chem, 37, 695, 10.1093/clinchem/37.5.695 · DOI · Paper page
  85. Cockcroft, 1976, Prediction of creatinine clearance from serum creatinine, Nephron, 16, 31
  86. Morrow, 2007, Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial, JAMA, 297, 1775, 10.1001/jama.297.16.1775 · DOI · Paper page
  87. Coll, 2000, Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment, Am J Kidney Dis, 36, 29, 10.1053/ajkd.2000.8237 · DOI · Paper page
  88. Shlipak, 2005, Cystatin C and the risk of death and cardiovascular events among elderly persons, N Engl J Med, 352, 2049, 10.1056/NEJMoa043161 · DOI · Paper page
  89. Jernberg, 2004, Cystatin C: a novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome, Circulation, 110, 2342, 10.1161/01.CIR.0000145166.44942.E0 · DOI · Paper page
  90. Baldus, 2003, Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes, Circulation, 108, 1440, 10.1161/01.CIR.0000090690.67322.51 · DOI · Paper page
  91. Brennan, 2003, Prognostic value of myeloperoxidase in patients with chest pain, N Engl J Med, 349, 1595, 10.1056/NEJMoa035003 · DOI · Paper page
  92. Heeschen, 2003, Soluble CD40 ligand in acute coronary syndromes, N Engl J Med, 348, 1104, 10.1056/NEJMoa022600 · DOI · Paper page
  93. Varo, 2003, Soluble CD40L: risk prediction after acute coronary syndromes, Circulation, 108, 1049, 10.1161/01.CIR.0000088521.04017.13 · DOI · Paper page
  94. Antman, 1995, Evaluation of a rapid bedside assay for detection of serum cardiac troponin T, JAMA, 273, 1279, 10.1001/jama.1995.03520400049043 · DOI
  95. Ohman, 1999, Risk stratification with a point-of-care cardiac troponin T test in acute myocardial infarction. GUSTOIII Investigators. Global Use of Strategies To Open Occluded Coronary Arteries, Am J Cardiol, 84, 1281, 10.1016/S0002-9149(99)00558-5 · DOI
  96. Wu, 1999, National Academy of Clinical Biochemistry Standards of Laboratory Practice: recommendations for the use of cardiac markers in coronary artery diseases, Clin Chem, 45, 1104, 10.1093/clinchem/45.7.1104 · DOI · Paper page
  97. Sylven, 1998, Excellent reliability of nurse-based bedside diagnosis of acute myocardial infarction by rapid dry-strip creatine kinase MB, myoglobin, and troponin T, Am Heart J, 135, 677, 10.1016/S0002-8703(98)70285-6 · DOI
  98. Muller-Bardorff, 1999, Quantitative bedside assay for cardiac troponin T: a complementary method to centralized laboratory testing, Clin Chem, 45, 1002, 10.1093/clinchem/45.7.1002 · DOI
  99. Cheitlin, 2003, ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography), Circulation, 108, 1146, 10.1161/01.CIR.0000073597.57414.A9 · DOI · Paper page
  100. Amanullah, 1992, Predischarge exercise echocardiography in patients with unstable angina who respond to medical treatment, Clin Cardiol, 15, 417, 10.1002/clc.4960150605 · DOI
  101. Amanullah, 1993, Prognostic significance of exercise thallium-201 myocardial perfusion imaging compared to stress echocardiography and clinical variables in patients with unstable angina who respond to medical treatment, Int J Cardiol, 39, 71, 10.1016/0167-5273(93)90298-U · DOI
  102. Brown, 1991, Prognostic value of thallium-201 myocardial perfusion imaging in patients with unstable angina who respond to medical treatment, J Am Coll Cardiol, 17, 1053, 10.1016/0735-1097(91)90829-X · DOI
  103. Kwong, 2003, Detecting acute coronary syndrome in the emergency department with cardiac magnetic resonance imaging, Circulation, 107, 531, 10.1161/01.CIR.0000047527.11221.29 · DOI · Paper page
  104. Udelson, 2002, Myocardial perfusion imaging for evaluation and triage of patients with suspected acute cardiac ischemia: a randomized controlled trial, JAMA, 288, 2693, 10.1001/jama.288.21.2693 · DOI · Paper page
  105. Luchi, 1987, Comparison of medical and surgical treatment for unstable angina pectoris. Results of a Veterans Administration Cooperative Study, N Engl J Med, 316, 977, 10.1056/NEJM198704163161603 · DOI
  106. Dirksen, 2005, Cardiac multidetector-row computed tomography in patients with unstable angina, Am J Cardiol, 95, 457, 10.1016/j.amjcard.2004.10.010 · DOI
  107. Hasdai, 2003, Acute coronary syndromes in patients with pre-existing moderate to severe valvular disease of the heart: lessons from the Euro-Heart Survey of acute coronary syndromes, Eur Heart J, 24, 623, 10.1016/S0195-668X(02)00742-X · DOI
  108. Smeeth, 2004, Risk of myocardial infarction and stroke after acute infection or vaccination, N Engl J Med, 351, 2611, 10.1056/NEJMoa041747 · DOI · Paper page
  109. Fedullo, 2003, Clinical practice. The evaluation of suspected pulmonary embolism, N Engl J Med, 349, 1247, 10.1056/NEJMcp035442 · DOI · Paper page
  110. James, 2000, Relation between troponin T concentration and mortality in patients presenting with an acute stroke: observational study, BMJ, 320, 1502, 10.1136/bmj.320.7248.1502 · DOI
  111. Fox, 2006, Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE), BMJ, 333, 1091, 10.1136/bmj.38985.646481.55 · DOI · Paper page
  112. Granger, 2003, Predictors of hospital mortality in the global registry of acute coronary events, Arch Intern Med, 163, 2345, 10.1001/archinte.163.19.2345 · DOI · Paper page
  113. de Araujo Goncalves, 2005, TIMI, PURSUIT, and GRACE risk scores: sustained prognostic value and interaction with revascularization in NSTE-ACS, Eur Heart J, 26, 865, 10.1093/eurheartj/ehi187 · DOI · Paper page
  114. Antman, 2000, The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making, JAMA, 284, 835, 10.1001/jama.284.7.835 · DOI · Paper page
  115. Lagerqvist, 2005, FRISC score for selection of patients for an early invasive treatment strategy in unstable coronary artery disease, Heart, 91, 1047, 10.1136/hrt.2003.031369 · DOI
  116. Lagerqvist, 2006, 5-year outcomes in the FRISC-II randomised trial of an invasive versus a non-invasive strategy in non-ST-elevation acute coronary syndrome: a follow-up study, Lancet, 368, 998, 10.1016/S0140-6736(06)69416-6 · DOI · Paper page
  117. Boersma, 2000, Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators, Circulation, 101, 2557, 10.1161/01.CIR.101.22.2557 · DOI · Paper page
  118. Telford, 1981, Trial of heparin versus atenolol in prevention of myocardial infarction in intermediate coronary syndrome, Lancet, 1, 1225, 10.1016/S0140-6736(81)92399-0 · DOI · Paper page
  119. Lubsen, 1987, Efficacy of nifedipine and metoprolol in the early treatment of unstable angina in the coronary care unit: findings from the Holland Interuniversity Nifedipine/metoprolol Trial (HINT), Am J Cardiol, 60, 18A, 10.1016/0002-9149(87)90494-2 · DOI
  120. Yusuf, 1988, Overview of results of randomized clinical trials in heart disease. II. Unstable angina, heart failure, primary prevention with aspirin, and risk factor modification, JAMA, 260, 2259, 10.1001/jama.1988.03410150107041 · DOI
  121. The MIAMI Trial Research Group, 1985, Metoprolol in acute myocardial infarction (MIAMI). A randomised placebo-controlled international trial, Eur Heart J, 6, 199, 10.1093/oxfordjournals.eurheartj.a061845 · DOI · Paper page
  122. Kaplan, 1983, Intravenous nitroglycerin for the treatment of angina at rest unresponsive to standard nitrate therapy, Am J Cardiol, 51, 694, 10.1016/S0002-9149(83)80117-9 · DOI
  123. DePace, 1982, Intravenous nitroglycerin for rest angina. Potential pathophysiologic mechanisms of action, Arch Intern Med, 142, 1806, 10.1001/archinte.1982.00340230046009 · DOI
  124. Roubin, 1982, Intravenous nitroglycerine in refractory unstable angina pectoris, Aust N Z J Med, 12, 598, 10.1111/j.1445-5994.1982.tb02645.x · DOI
  125. Curfman, 1983, Intravenous nitroglycerin in the treatment of spontaneous angina pectoris: a prospective, randomized trial, Circulation, 67, 276, 10.1161/01.CIR.67.2.276 · DOI
  126. Dellborg, 1991, Buccal versus intravenous nitroglycerin in unstable angina pectoris, Eur J Clin Pharmacol, 41, 5, 10.1007/BF00280098 · DOI
  127. Theroux, 1985, A randomized study comparing propranolol and diltiazem in the treatment of unstable angina, J Am Coll Cardiol, 5, 717, 10.1016/S0735-1097(85)80400-9 · DOI
  128. Parodi, 1986, Comparison of verapamil and propranolol therapy for angina pectoris at rest: a randomized, multiple-crossover, controlled trial in the coronary care unit, Am J Cardiol, 57, 899, 10.1016/0002-9149(86)90727-7 · DOI
  129. Smith, 1998, Health outcomes associated with beta-blocker and diltiazem treatment of unstable angina, J Am Coll Cardiol, 32, 1305, 10.1016/S0735-1097(98)00408-2 · DOI
  130. Gibson, 1987, Prognostic significance and beneficial effect of diltiazem on the incidence of early recurrent ischemia after non-Q-wave myocardial infarction: results from the Multicenter Diltiazem Reinfarction Study, Am J Cardiol, 60, 203, 10.1016/0002-9149(87)90214-1 · DOI
  131. Held, 1989, Calcium channel blockers in acute myocardial infarction and unstable angina: an overview, BMJ, 299, 1187, 10.1136/bmj.299.6709.1187 · DOI · Paper page
  132. Psaty, 1995, The risk of myocardial infarction associated with antihypertensive drug therapies, JAMA, 274, 620, 10.1001/jama.1995.03530080036038 · DOI · Paper page
  133. Yusuf, 1991, Update of effects of calcium antagonists in myocardial infarction or angina in light of the second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies, Am J Cardiol, 67, 1295, 10.1016/0002-9149(91)90944-G · DOI · Paper page
  134. Boden, 2000, Diltiazem in acute myocardial infarction treated with thrombolytic agents: a randomised placebo-controlled trial. Incomplete Infarction Trial of European Research Collaborators Evaluating Prognosis post-Thrombolysis (INTERCEPT), Lancet, 355, 1751, 10.1016/S0140-6736(00)02262-5 · DOI
  135. Borer, 2006, Therapeutic effects of I(f) blockade: evidence and perspective, Pharmacol Res, 53, 440, 10.1016/j.phrs.2006.03.017 · DOI
  136. McClellan, 1999, Trimetazidine. A review of its use in stable angina pectoris and other coronary conditions, Drugs, 58, 143, 10.2165/00003495-199958010-00016 · DOI
  137. Chaitman, 2006, Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions, Circulation, 113, 2462, 10.1161/CIRCULATIONAHA.105.597500 · DOI · Paper page
  138. IONA Study Group, 2002, Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial, Lancet, 359, 1269, 10.1016/S0140-6736(02)08265-X · DOI · Paper page
  139. Harrington, 2004, Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy, Chest, 126, 513S, 10.1378/chest.126.3_suppl.513S · DOI
  140. Hirsh, 2004, Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy, Chest, 126, 188S, 10.1378/chest.126.3_suppl.188S · DOI · Paper page
  141. Theroux, 1988, Aspirin, heparin, or both to treat acute unstable angina, N Engl J Med, 319, 1105, 10.1056/NEJM198810273191701 · DOI · Paper page
  142. Eikelboom, 2000, Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis, Lancet, 355, 1936, 10.1016/S0140-6736(00)02324-2 · DOI · Paper page
  143. Collins, 1996, Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials, BMJ, 313, 652, 10.1136/bmj.313.7058.652 · DOI
  144. Oler, 1996, Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis, JAMA, 276, 811, 10.1001/jama.1996.03540100055028 · DOI · Paper page
  145. Antman, 1999, Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial, Circulation, 100, 1593, 10.1161/01.CIR.100.15.1593 · DOI · Paper page
  146. Cohen, 1997, A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group, N Engl J Med, 337, 447, 10.1056/NEJM199708143370702 · DOI · Paper page
  147. Fragmin and Fast Revascularisation During Instability in Coronary Artery Disease Investigators, 1999, Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study, Lancet, 354, 701, 10.1016/S0140-6736(99)07350-X · DOI · Paper page
  148. Fragmin During Instability in Coronary Artery Disease (FRISC) Study Group, 1996, Low-molecular-weight heparin during instability in coronary artery disease, Lancet, 347, 561, 10.1016/S0140-6736(96)91270-2 · DOI · Paper page
  149. Klein, 1997, Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC), Circulation, 96, 61, 10.1161/01.CIR.96.1.61 · DOI · Paper page
  150. TIMI 11A Investigators, 1997, Dose-ranging trial of enoxaparin for unstable angina: results of TIMI 11A. The Thrombolysis in Myocardial Infarction (TIMI) 11A Trial Investigators, J Am Coll Cardiol, 29, 1474, 10.1016/S0735-1097(97)00094-6 · DOI
  151. Fragmin During Instability in Coronary Artery Disease (FRISC) Study Group, 1996, Low-molecular-weight heparin during instability in coronary artery disease, Lancet, 347, 561, 10.1016/S0140-6736(96)91270-2 · DOI · Paper page
  152. Gurfinkel, 1995, Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia, J Am Coll Cardiol, 26, 313, 10.1016/0735-1097(95)80001-W · DOI · Paper page
  153. 1999, FRAX.I.S. (FRAxiparine in Ischemic Syndromes) Investigators. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (Fraxiparine in Ischaemic Syndrome), Eur Heart J, 20, 1553, 10.1053/euhj.1999.1879 · DOI
  154. Lindahl, 1998, The FRISC experience with troponin T. Use as decision tool and comparison with other prognostic markers, Eur Heart J, 19, N51
  155. Blazing, 2004, Safety and efficacy of enoxaparin vs. unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial, JAMA, 292, 55, 10.1001/jama.292.1.55 · DOI · Paper page
  156. Cohen, 2002, Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study. The antithrombotic combination using tirofiban and enoxaparin, Am Heart J, 144, 470, 10.1067/mhj.2002.126115 · DOI
  157. Goodman, 2003, Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide, Circulation, 107, 238, 10.1161/01.CIR.0000050144.67910.13 · DOI
  158. Ferguson, 2004, Enoxaparin vs. unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial, JAMA, 292, 45
  159. Petersen, 2004, Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-segment elevation acute coronary syndromes: a systematic overview, JAMA, 292, 89, 10.1001/jama.292.1.89 · DOI · Paper page
  160. Yusuf, 2006, Effects of Fondaparinux, a factor Xa inhibitor, on mortality and reinfarction in patients with acute myocardial infarction presenting with ST-segment elevation. Organization to Assess Strategies for Ischemic Syndromes (OASIS)-6 Investigators, JAMA, 295, 1519, 10.1001/jama.295.13.joc60038 · DOI · Paper page
  161. Alexander, 2005, Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes, JAMA, 294, 3108, 10.1001/jama.294.24.3108 · DOI · Paper page
  162. Ferguson, 2003, Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study, Am Heart J, 146, 628, 10.1016/S0002-8703(03)00165-0 · DOI
  163. James, 2002, Safety and efficacy of abciximab combined with dalteparin in treatment of acute coronary syndromes, Eur Heart J, 23, 1538, 10.1053/euhj.2002.3257 · DOI
  164. Mukherjee, 2002, Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B), Am Heart J, 144, 995, 10.1067/mhj.2002.126118 · DOI
  165. Zeymer, 2006, Clinical benefit of enoxaparin in patients with high-risk acute coronary syndromes without ST elevations in clinical practice, Am J Cardiol, 98, 19, 10.1016/j.amjcard.2006.01.047 · DOI
  166. Simoons, 2004, A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes: the Pentasaccharide in Unstable Angina (PENTUA) Study, J Am Coll Cardiol, 43, 2183, 10.1016/j.jacc.2004.02.051 · DOI
  167. Mehta, 2005, Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot Trial, Circulation, 111, 1390, 10.1161/01.CIR.0000158485.70761.67 · DOI
  168. 2005, Design and rationale of the MICHELANGELO. Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non-ST-segment elevation acute coronary syndromes, Am Heart J, 150, 1107
  169. Yusuf, 2006, Efficacy and safety of fondaparinux compared to enoxaparin in 20,078 patients with acute coronary syndromes without ST segment elevation. The OASIS (Organization to Assess Strategies in Acute Ischemic Syndromes)-5 Investigators, N Engl J Med, 354, 1464
  170. Direct Thrombin Inhibitor Trialists' Collaborative Group, 2002, Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data, Lancet, 359, 294, 10.1016/S0140-6736(02)07495-0 · DOI
  171. Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators, 1999, Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial, Lancet, 353, 429, 10.1016/S0140-6736(98)07332-2 · DOI · Paper page
  172. Bittl, 2001, Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: final report reanalysis of the Bivalirudin Angioplasty Study, Am Heart J, 142, 952, 10.1067/mhj.2001.119374 · DOI · Paper page
  173. Lincoff, 2003, Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial, JAMA, 289, 853, 10.1001/jama.289.7.853 · DOI · Paper page
  174. Lincoff, 2004, Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs. heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial, JAMA, 292, 696, 10.1001/jama.292.6.696 · DOI · Paper page
  175. Silber, 2005, Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology, Eur Heart J, 26, 804, 10.1093/eurheartj/ehi138 · DOI · Paper page
  176. Dang, 2006, Evaluation of treatment with direct thrombin inhibitors in patients with heparin-induced thrombocytopenia, Pharmacotherapy, 26, 461, 10.1592/phco.26.4.461 · DOI
  177. Lubenow, 2001, Drugs for the prevention and treatment of thrombosis in patients with heparin-induced thrombocytopenia, Am J Cardiovasc Drugs, 1, 429, 10.2165/00129784-200101060-00003 · DOI
  178. Warkentin, 2003, Management of heparin-induced thrombocytopenia: a critical comparison of lepirudin and argatroban, Thromb Res, 110, 73, 10.1016/S0049-3848(03)00336-0 · DOI
  179. Stone, 2004, Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale, Am Heart J, 148, 764, 10.1016/j.ahj.2004.04.036 · DOI
  180. Stone, 2006, Bivalirudin for patients with acute coronary syndromes, N Engl J Med, 355, 2203, 10.1056/NEJMoa062437 · DOI · Paper page
  181. Kastrati, 2006, Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial, JAMA, 295, 1531, 10.1001/jama.295.13.joc60034 · DOI · Paper page
  182. Brown, 2006, An introductory note to the CHMP guidelines: choice of the non-inferiority margin and data monitoring committees, Stat Med, 25, 1623, 10.1002/sim.2561 · DOI
  183. Committee for Medicinal Products for Human Use (CHMP), 2006, Guideline on the choice of the non-inferiority margin, Stat Med, 25, 1628, 10.1002/sim.2584 · DOI
  184. Andres, 2001, An approximate unconditional test of non-inferiority between two proportions, Stat Med, 20, 2206
  185. Brown, 2006, An introductory note to CHMP guidelines: choice of the non-inferiority margin and data monitoring committees, Stat Med, 25, 1623, 10.1002/sim.2561 · DOI
  186. Chow, 2006, On non-inferiority margin and statistical tests in active control trials, Stat Med, 25, 1101, 10.1002/sim.2208 · DOI
  187. Hung, 2005, A regulatory perspective on choice of margin and statistical inference issue in non-inferiority trials, Biometrical J, 47, 28, 10.1002/bimj.200410084 · DOI
  188. Kang, 2000, An approximate unconditional test of non-inferiority between two proportions, Stat Med, 19, 2089, 10.1002/1097-0258(20000830)19:16<2089::AID-SIM537>3.0.CO;2-B · DOI
  189. Sidik, 2003, Exact unconditional tests for testing non-inferiority in matched-pairs design, Stat Med, 22, 265, 10.1002/sim.1261 · DOI
  190. Kaul, 2007, Making sense of noninferiority: a clinical and statistical perspective on its application to cardiovascular clinical trials, Prog Cardiovasc Dis, 49, 284, 10.1016/j.pcad.2006.10.001 · DOI
  191. Ansell, 2004, The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy, Chest, 126, 204S, 10.1378/chest.126.3_suppl.204S · DOI · Paper page
  192. Hurlen, 2002, Warfarin, aspirin, or both after myocardial infarction, N Engl J Med, 347, 969, 10.1056/NEJMoa020496 · DOI · Paper page
  193. Andreotti, 2006, Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25 307 patients, Eur Heart J, 27, 519, 10.1093/eurheartj/ehi485 · DOI · Paper page
  194. Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators, 2001, Effects of long-term, moderate-intensity oral anticoagulation in addition to aspirin in unstable angina, J Am Coll Cardiol, 37, 475, 10.1016/S0735-1097(00)01118-9 · DOI
  195. Buresly, 2005, Bleeding complications associated with combinations of aspirin, thienopyridine derivatives, and warfarin in elderly patients following acute myocardial infarction, Arch Intern Med, 165, 784, 10.1001/archinte.165.7.784 · DOI
  196. Natarajan, 2006, A randomized pilot study of dalteparin versus unfractionated heparin during percutaneous coronary interventions, Am Heart J, 151, 175, 10.1016/j.ahj.2005.06.020 · DOI
  197. Popma, 2004, Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy, Chest, 126, 576S, 10.1378/chest.126.3_suppl.576S · DOI
  198. Montalescot, 2006, Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention, N Engl J Med, 355, 1006, 10.1056/NEJMoa052711 · DOI · Paper page
  199. Majure, 2006, Fondaparinux versus enoxaparin in acute coronary syndromes, N Engl J Med, 354, 2829, 10.1056/NEJMc061206 · DOI
  200. Theroux, 1993, Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina, Circulation, 88, 2045, 10.1161/01.CIR.88.5.2045 · DOI · Paper page

200 of 483 shown

Cited by

See all 1,849

Metadata

Authors
Authors/Task Force Members, Bassand, J.-P., Hamm, C. W., Ardissino, D., Boersma, E., Budaj, A., Fernandez-Aviles, F., Fox, K. A. A., Hasdai, D., Ohman, E. M., Wallentin, L., Wijns, W., ESC Committee for Practice Guidelines (CPG), Vahanian, A., Camm, J., De Caterina, R., Dean, V., Dickstein, K., Filippatos, G., Kristensen, S. D., Widimsky, P., McGregor, K., Sechtem, U., Tendera, M., Hellemans, I., Gomez, J. L. Z., Silber, S., Funck-Brentano, C., Reviewers, D., Kristensen, S. D., Andreotti, F., Benzer, W., Bertrand, M., Betriu, A., De Caterina, R., DeSutter, J., Falk, V., Ortiz, A. F., Gitt, A., Hasin, Y., Huber, K., Kornowski, R., Lopez-Sendon, J., Morais, J., Nordrehaug, J. E., Silber, S., Steg, P. G., Thygesen, K., Tubaro, M., Turpie, A. G. G., Verheugt, F., & Windecker, S.
Venue
European Heart Journal
Publisher
Oxford University Press (OUP)
Published
2007-05-05
Volume
28
Issue
13
Pages
1598-1660
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
DOI
10.1093/eurheartj/ehm161
OpenAlex
W2131370832
Cited by
1,849
References
31
FWCI
169.57
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.